Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon α-2b and ribavirin therapy?

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 568–569 (2005)Cite this article

boxed-textMangia A et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609–2617

Monitoring the virologic response at 4 weeks might allow clinicians to individualize treatment regimens for patients infected with HCV genotype 2 or 3

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hadziyannis SJ et al. (2004) Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355

    Article  CAS  Google Scholar 

  2. Dalgard O et al. (2004) Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40: 160–1265

    Article  Google Scholar 

  3. Sanchez-Tapias JM et al. (2004) Longer treatment duration with peginterferon alfa-2a (40kD) (Pegasys) and ribavirin (Copegus) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter TERAVIC-4 Study [abstract]. Hepatology 40 (Suppl 1): 126A

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Katy Cherry, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Clinical Director of Hepatology at Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA

    Andrew J Muir

Authors
  1. Andrew J Muir
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Research support/grants from Schering-Plough and Roche.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muir, A. HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon α-2b and ribavirin therapy?. Nat Rev Gastroenterol Hepatol 2, 568–569 (2005). https://doi.org/10.1038/ncpgasthep0337

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0337

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing